Increasing the Levels of Insulin-Like Growth Factor-I by an IGF Binding Protein Inhibitor Produces Anxiolytic and Antidepressant-Like Effects
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
The present studies were conducted to determine if increasing central levels of the neurotrophic factor insulin-like growth factor-1 (IGF-I) either directly or indirectly produces anxiolytic and antidepressant-like effects in the mouse. Central levels of IGF-I can be increased directly, by administering IGF-I, or indirectly by blocking the insulin-like growth factor binding proteins (IGFBPs). The IGFBP family has the unique ability to regulate IGF-I levels by sequestering IGF-I into an inactive complex. Therefore, an IGFBP inhibitor increases the level of IGF-I available to bind to its receptor. Intracerebroventricular (icv) administration of the nonspecific IGFBP inhibitor NBI-31772 (10-30 microg) increases the number of punished crossings in the four-plate test and NBI-31772 (0.3-10 microg) increases time spent in the open quadrant of the elevated zero maze (EZM), indicative of anxiolytic-like effects. NBI-31772 (3-30 microg) also decreases immobility time in the tail suspension test, indicative of antidepressant-like effects. Similarly, icv administration of IGF-I (0.1 microg) produces anxiolytic-like effects in the four-plate test and IGF-1 (0.3-1 microg) produces anxiolytic-like effects in the EZM. IGF-I (10 microg) also produces antidepressant-like effects in the tail suspension test. Coadministration of the IGF-I receptor antagonist JB1 with NBI-31772 or IGF-I blocks the anxiolytic-like and antidepressant-like effects of these compounds. These results suggest that NBI-…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, an increase of peripheral IGF-1 by direct injection of IGF-1 or inhibition of IGF-1 binding protein displayed anxiolytic and antidepressant effects in rodents (Duman et al. 2009; Hoshaw et al. 2005; Malberg et al. 2007; Park et al. 2011)”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Malberg et al. 2007
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391 · cited 1×
“Despite the high prevalence of depressive and anxiety disorders in the population (Berton and Nestler, 2006; Kessler et al, 2005; Malberg and Schechter, 2005), our understanding of the mechanisms by which antidepressant and anxiolytic drugs produce their effects are limited.”
BackgroundValidation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
Pellow, S., Chopin, P., File, S. E., & Briley, M. (1985) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(85)90031-7 · Cited by 5,822 · cited 1×
“Compounds that increase the percentage time an animal spends in the open quadrants Neuropsychopharmacology of the EZM, compared to the closed quadrants, are considered to exhibit anxiolytic-like activity (Kash et al, 1999; Pellow et al, 1985).”
BackgroundThe tail suspension test: A new method for screening antidepressants in mice
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985) · Psychopharmacology · doi:10.1007/bf00428203 · Cited by 3,534 · cited 1×
“The procedure followed in this study is a variant of the one originally described by Steru et al (1985).”
MethodNestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00653-0 · Cited by 3,217
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111 · cited 1×
“This difference in time course between the acute behavioral effects and the chronic administration necessary for cell proliferation has also been seen with clinically effective antidepressant such as fluoxetine (Malberg et al, 2000).”
BackgroundSelf-citationNew approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589 · cited 1×
“Despite the high prevalence of depressive and anxiety disorders in the population (Berton and Nestler, 2006; Kessler et al, 2005; Malberg and Schechter, 2005), our understanding of the mechanisms by which antidepressant and anxiolytic drugs produce their effects are limited.”
BackgroundThe Somatomedin Hypothesis: 2001
Le Roith, D., Bondy, C., Yakar, S., Liu, J.-L., & Butler, A. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.1.0419 · Cited by 1,257 · cited 1×
“IGF-I was first named ‘somatomedin C’ owing to its ability to mediate the effect of somatotropin (growth hormone) (Le Roith et al, 2001).”
BackgroundBrunet, A., Datta, S. R., & Greenberg, M. E. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00211-7 · Cited by 1,188 · cited 1×
“This receptor signaling pathway activates both the Ras/mitogen-activated protein kinase pathway and the PI3 kinase–AKT pathways (Brunet et al, 2001; Ye and D’Ercole, 2006).”
BackgroundPeripheral Infusion of IGF-I Selectively Induces Neurogenesis in the Adult Rat Hippocampus
Åberg, M. A. I., Åberg, N. D., Hedbäcker, H., Oscarsson, J., & Eriksson, P. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-08-02896.2000 · Cited by 852 · cited 2×
“It has been shown that IGF-I produces increases in cell proliferation and neurogenesis in vivo (Aberg et al, 2000).”
BackgroundShepherd, J. K., Grewal, S. S., Fletcher, A., Bill, D. J., & Dourish, C. T. (1994) · Psychopharmacology · doi:10.1007/bf02244871 · Cited by 739 · cited 2×
“The EZM is a modification of the elevated plus maze and consists of a circular platform (outer diameter approximately 60 cm, width 5 cm) that is elevated 55 cm above the floor, and made of black Perspex (Shepherd et al, 1994).”
BackgroundShimasaki, S., & Ling, N. (1991) · Progress in Growth Factor Research · doi:10.1016/0955-2235(91)90003-m · Cited by 674 · cited 1×
“There are six members of the IGFBP family, which are found throughout the peripheral and central nervous systems (Shimasaki and Ling, 1991).”
BackgroundRole of Neurotrophic Factors in the Etiology and Treatment of Mood Disorders
Duman, R. S. (2004) · NeuroMolecular Medicine · doi:10.1385/nmm:5:1:011 · Cited by 537 · cited 1×
“More recent clinical and preclinical research in depression (Duman, 2004; Nestler et al, 2002) has begun to focus on the role of growth factors and neurotrophic factors in depression and antidepressant action.”
BackgroundCentral administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects
Hoshaw, B. A., Malberg, J. E., & Lucki, I. (2005) · Brain Research · doi:10.1016/j.brainres.2005.01.007 · Cited by 348 · cited 3×
“This decrease in immobility indicates a putative antidepressant-like effect and is in agreement with previous data demonstrating antidepressant-like activity of IGF-I in the rat (Hoshaw et al, 2005).”
BackgroundResultInfluentialSelf-citationRing, R. H., Malberg, J. E., Potestio, L., Ping, J., Boikess, S., Luo, B., Schechter, L. E., Rizzo, S., Rahman, Z., & Rosenzweig-Lipson, S. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0293-z · Cited by 319 · cited 1×
“This injection method has been previously validated in our laboratory (Ring et al, 2006).”
MethodSelf-citationInsulin-like growth factor-I and neurogenesis in the adult mammalian brain
Anderson, M. F., Åberg, M. A. I., Nilsson, M., & Eriksson, P. S. (2002) · Developmental Brain Research · doi:10.1016/s0165-3806(02)00277-8 · Cited by 314 · cited 1×
“Both central (icv) and systemic administration of IGF-I increases hippocampal cell proliferation and neurogenesis in the adult rat (Aberg et al, 2000; Anderson et al, 2002).”
BackgroundIGF-I has a direct proliferative effect in adult hippocampal progenitor cells
Åberg, M. A. I., Åberg, N. D., Palmer, T. D., Alborn, A.-M., Carlsson-Skwirut, C., Bang, P., Rosengren, L. E., Olsson, T., Gage, F. H., & Eriksson, P. S. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00082-4 · Cited by 284 · cited 1×
“Although also found in the periphery, IGFBP2 and IGFBP4 are highly localized in the CSF, hippocampus, amygdala, cortex, thalamus, and basal ganglia, and are expressed in adult hippocampal progenitor cell cultures (Aberg et al, 2003; Brar and Chernausek, 1993; Logan et al, 1994).”
BackgroundMattson, M. P., Maudsley, S., & Martin, B. (2004) · Ageing Research Reviews · doi:10.1016/j.arr.2004.08.001 · Cited by 268 · cited 1×
“These pathways share a high degree of overlap with the signaling pathways of 5-HT and BDNF, which are also implicated in antidepressant action (Mattson et al, 2004).”
BackgroundInnovative approaches for the development of antidepressant drugs: Current and future strategies
Schechter, L. E., Ring, R. H., Beyer, C. E., Hughes, Z. A., Khawaja, X., Malberg, J. E., & Rosenzweig-Lipson, S. (2005) · NeuroRX · doi:10.1602/neurorx.2.4.590 · Cited by 228
Self-citationKash, S. F., Tecott, L. H., Hodge, C., & Baekkeskov, S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1698 · Cited by 216 · cited 1×
“Compounds that increase the percentage time an animal spends in the open quadrants Neuropsychopharmacology of the EZM, compared to the closed quadrants, are considered to exhibit anxiolytic-like activity (Kash et al, 1999; Pellow et al, 1985).”
BackgroundEvaluation of a rapid technique for detecting minor tranquilizers
Aron, C., Simon, P., Larousse, C., & Boissier, J. R. (1971) · Neuropharmacology · doi:10.1016/0028-3908(71)90074-8 · Cited by 169 · cited 1×
“Clinically effective classes of anxiolytic compounds such as benzodiazepines, selective serotonin reuptake inhibitors, or partial 5-HT1A agonists produce increases in punished crossings, which is indicative of anxiolytic-like activity (Aron et al, 1971; Bourin et al, 1992; Hascoet et al, 2000).”
BackgroundIncreasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs
Malberg, J., & Schechter, L. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053382223 · Cited by 167 · cited 3×
“…effective antidepressant drugs increase adult hippocampal neurogenesis in rodents, and a current hypothesis is that neurotrophins or drugs that modulate plasticity-related proteins or growth factors may provide the next generation of antidepressant or anxiolytic drugs (Malberg and Schechter, 2005).”
BackgroundSelf-citationAraujo, D. M., Lapchak, P. A., Collier, B., Chabot, J., & Quirion, R. (1989) · Brain Research · doi:10.1016/0006-8993(89)90355-7 · Cited by 150 · cited 1×
“However, in the mouse used in this study, IGF-1 may be hypothesized to reach additional structures such as the hippocampus and the amygdala, which are areas implicated in depression and antidepressant action (Nestler et al, 2002) and express IGF-1R mRNA (Araujo et al, 1989).”
MethodNovel Aspects of the Insulin-like Growth Factor Binding Proteins
Wetterau, L. A., Moore, M. G., Lee, K.-W., Shim, M. L., & Cohen, P. (1999) · Molecular Genetics and Metabolism · doi:10.1006/mgme.1999.2920 · Cited by 149 · cited 2×
“An IGFBP inhibitor can be used to increase IGF-I levels owing to the unique properties of the IGFBP family (Wetterau et al, 1999).”
BackgroundTargeting insulin-like growth factor pathways
Yee, D. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602963 · Cited by 122 · cited 2×
“IGF-I induces cell proliferation in multiple cell types and organ systems that may result in undesirable side effects (Yee, 2006).”
BackgroundKurihara, S., Hakuno, F., & Takahashi, S. (2000) · Endocrine Journal · doi:10.1507/endocrj.47.739 · Cited by 93 · cited 1×
“Insulin-like growth factor-1 (IGF-I) has a number of growth-promoting effects in the central nervous system (CNS), which qualify this molecule as a neurotrophin (Kim et al, 1998, 2004; Kurihara et al, 2000).”
BackgroundLogan, A. (1994) · Endocrinology · doi:10.1210/en.135.5.2255 · Cited by 92 · cited 1×
“Although also found in the periphery, IGFBP2 and IGFBP4 are highly localized in the CSF, hippocampus, amygdala, cortex, thalamus, and basal ganglia, and are expressed in adult hippocampal progenitor cell cultures (Aberg et al, 2003; Brar and Chernausek, 1993; Logan et al, 1994).”
BackgroundLoddick, S. A., Liu, X.-J., Lu, Z.-X., Liu, C., Behan, D. P., Chalmers, D. C., Foster, A. C., Vale, W. W., Ling, N., & De Souza, E. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1894 · Cited by 91 · cited 3×
“This nonpeptide ligand binds with high affinity to all six members of the IGFBP family (Liu et al, 2001) and has only low affinity for the IGF-IR and IGF-IIR (Chen et al, 2001; Loddick et al, 1998).”
BackgroundInsulin-like growth factor-I signaling in human neuroblastoma cells
Kim, B., van Golen, C. M., & Feldman, E. L. (2004) · Oncogene · doi:10.1038/sj.onc.1206924 · Cited by 91 · cited 1×
“Insulin-like growth factor-1 (IGF-I) has a number of growth-promoting effects in the central nervous system (CNS), which qualify this molecule as a neurotrophin (Kim et al, 1998, 2004; Kurihara et al, 2000).”
BackgroundYe, P., & D'Ercole, A. J. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20688 · Cited by 85 · cited 3×
“IGF-I signals through the IGF-IR via a multiprotein signaling complex (Ye and D’Ercole, 2006).”
BackgroundHawkes, C., Jhamandas, J. H., Harris, K. H., Fu, W., MacDonald, R. G., & Kar, S. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2730-05.2006 · Cited by 83 · cited 1×
“In contrast to the IGF-IR, the IGF-IIR primarily acts on intracellular trafficking of enzymes and IGF-II clearance (Hawkes and Kar, 2003; Yee, 2006), although recently Hawkes et al (2006) demonstrated that the IGF-IIR activates a G-protein sensitive, protein kinase C dependent pathway.”
BackgroundAnxiolytic-Like Effects of Antidepressants After Acute Administration in a Four-Plate Test in Mice
Hascoët, M., Bourin, M., Colombel, M. C., Fiocco, A. J., & Baker, G. B. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(99)00191-4 · Cited by 80 · cited 2×
“Clinically effective classes of anxiolytic compounds such as benzodiazepines, selective serotonin reuptake inhibitors, or partial 5-HT1A agonists produce increases in punished crossings, which is indicative of anxiolytic-like activity (Aron et al, 1971; Bourin et al, 1992; Hascoet et al, 2000).”
BackgroundChen, Zhu, Y., Liu, X.-J., Zixian, L., Xie, Q., & LING, N. C. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010304b · Cited by 78 · cited 8×
“IGF-I also binds to the IGF-IIR, also known as the IGF-II/ mannose-6-phospate receptor, albeit at a much reduced potency (4100-fold difference) than for the IGF-I (Loddick et al, 1998).”
BackgroundInfluentialStouthart, P. J. H. M., Deijen, J. B., Roffel, M., & de Waal, H. A. D. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00045-8 · Cited by 74 · cited 2×
“In contrast, cessation of GH treatment, which produced a decrease in IGF-I levels, also produced an increase in depression and other negative symptoms and complaints (McMillan et al, 2003; Stouthart et al, 2003).”
BackgroundNagaraja, T. N., Patel, P., Gorski, M., Gorevic, P. D., Patlak, C. S., & Fenstermacher, J. D. (2005) · Cerebrospinal Fluid Research · doi:10.1186/1743-8454-2-5 · Cited by 74 · cited 1×
“A recent study by Nagaraja et al (2005) has investigated the time course of IGF-I clearance in the rat after a single icv Figure 6 The effects of IGF-I or NBI-31772 on spontaneous locomotor activity.”
MethodHawkes, C., & Kar, S. (2003) · Journal of Comparative Neurology · doi:10.1002/cne.10578 · Cited by 66 · cited 1×
“In contrast to the IGF-IR, the IGF-IIR primarily acts on intracellular trafficking of enzymes and IGF-II clearance (Hawkes and Kar, 2003; Yee, 2006), although recently Hawkes et al (2006) demonstrated that the IGF-IIR activates a G-protein sensitive, protein kinase C dependent pathway.”
BackgroundBourin, M., Hascoët, M., Mansouri, B., Colombel, M. C., & Bradwejn, J. (1992) · PubMed · Cited by 60
Mackay, K. B., Loddick, S. A., Naeve, G. S., Vana, A. M., Verge, G. M., & Foster, A. C. (2003) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000087091.01171.ae · Cited by 59 · cited 4×
“In vivo, NBI-31772 produces neuroprotective effects in a similar manner to exogenously administered IGF-I (Mackay et al, 2003).”
BackgroundInfluentialMcMillan, C. V., Bradley, C., Gibney, J., Healy, M. L., Russell‐Jones, D. L., & Sönksen, P. H. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01870.x · Cited by 56 · cited 1×
“In contrast, cessation of GH treatment, which produced a decrease in IGF-I levels, also produced an increase in depression and other negative symptoms and complaints (McMillan et al, 2003; Stouthart et al, 2003).”
BackgroundWallymahmed, M. E., Baker, G. A., Humphris, G., Dewey, M., & MacFarlane, I. A. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.704523.x · Cited by 55 · cited 1×
“Clinically, reduced serum IGF-I levels are seen in patients with growth hormone (GH) deficiency and depressive symptoms have been reported in these populations (Wallymahmed et al, 1996), although this has not been seen in all studies (Zenker et al, 2002).”
BackgroundBrar, A. K., & Chernausek, S. D. (1993) · Journal of Neuroscience Research · doi:10.1002/jnr.490350112 · Cited by 52 · cited 1×
“Although also found in the periphery, IGFBP2 and IGFBP4 are highly localized in the CSF, hippocampus, amygdala, cortex, thalamus, and basal ganglia, and are expressed in adult hippocampal progenitor cell cultures (Aberg et al, 2003; Brar and Chernausek, 1993; Logan et al, 1994).”
BackgroundImpact of Growth Hormone (GH) Therapy on Quality of Life along the Lifespan of GH-Treated Patients
Stabler, B. (2001) · Hormone Research in Paediatrics · doi:10.1159/000048136 · Cited by 47 · cited 1×
“In addition, children with GH deficiency (compared to children with normal GH but short stature) exhibit both depression and anxiety, and these conditions are reduced by GH treatment (Stabler, 2001).”
BackgroundLiu, X.-J., Xie, Q., Zhu, Y., Chen, C., & LING, N. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100299200 · Cited by 46 · cited 3×
“This nonpeptide ligand binds with high affinity to all six members of the IGFBP family (Liu et al, 2001) and has only low affinity for the IGF-IR and IGF-IIR (Chen et al, 2001; Loddick et al, 1998).”
BackgroundCeuninck, F. D., Caliez, A., Dassencourt, L., Anract, P., & Renard, P. (2004) · Arthritis Research & Therapy · doi:10.1186/ar1201 · Cited by 46 · cited 1×
“In addition, NBI-31772 can antagonize the inhibitory effect of IGFBP3 on anabolic responses in human chondrocytes (De Ceuninck et al, 2004).”
BackgroundKim, B., Leventhal, P. S., White, M. F., & Feldman, E. L. (1998) · Endocrinology · doi:10.1210/endo.139.12.6348 · Cited by 40
Elmlinger, M. W., Sanatani, M. S., Bell, M. A., Dannecker, G., & Ranke, M. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1380337 · Cited by 33 · cited 7×
“IGF-I also binds to the IGF-IIR, also known as the IGF-II/ mannose-6-phospate receptor, albeit at a much reduced potency (4100-fold difference) than for the IGF-I (Loddick et al, 1998).”
BackgroundInfluentialZenker, S., Haverkamp, F., & Klingmüller, D. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1470165 · Cited by 23 · cited 1×
“Clinically, reduced serum IGF-I levels are seen in patients with growth hormone (GH) deficiency and depressive symptoms have been reported in these populations (Wallymahmed et al, 1996), although this has not been seen in all studies (Zenker et al, 2002).”
BackgroundPavel, M., Lohmann, T., Hahn, E. G., & Hoffmann, M. M. (2003) · Hormone and Metabolic Research · doi:10.1055/s-2003-39058 · Cited by 14 · cited 1×
“Interestingly, Pavel et al (2003) have demonstrated that adult patients who received GH treatment had an improvement in mood.”
Background
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Mechanisms and Functional Implications of Adult Neurogenesis
Zhao, C., Deng, W., & Gage, F. H. (2008) · Cell · doi:10.1016/j.cell.2008.01.033 · Cited by 3,007
“Similarly, infusion of IGF1 elicits anxiolytic and antidepressant-like effects in behavioral tests (Malberg et al., 2007), and systematic administration of IGF1 increases SGZ neurogenesis (see references in Duman and Monteggia, 2006).”
Sex-Specific Programming of Offspring Emotionality after Stress Early in Pregnancy
Mueller, B. R., & Bale, T. L. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1424-08.2008 · Cited by 988
“Reductions in growth factors have been linked to affective and neurodevelopmental disorders (Malberg et al., 2007).”
BackgroundFunctional Biomarkers of Depression: Diagnosis, Treatment, and Pathophysiology
Schmidt, H. D., Shelton, R. C., & Duman, R. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.151 · Cited by 474
“Chronic antidepressant administration increases IGF-1 expression in the rat brain (Khawaja et al, 2004), and IGF-1 regulates adult hippocampal neurogenesis (Anderson et al, 2002) and produces antidepressant behavioral responses (Hoshaw et al, 2005; Malberg et al, 2007).”
BackgroundNeurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression
Levy, M. J. F., Boulle, F., Steinbusch, H. W., van den Hove, D. L. A., Kenis, G., & Lanfumey, L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4950-4 · Cited by 308
Metadata
- Authors
- Malberg, J. E., Platt, B., Rizzo, S. J. S., Ring, R. H., Lucki, I., Schechter, L. E., & Rosenzweig-Lipson, S.
- Affiliations
- Wyeth (US)
- University of Pennsylvania (US)
- Corresponding author
- Malberg, Jessica E
- Venue
- Neuropsychopharmacology
- Published
- 2007-03-07
- Volume
- 32
- Issue
- 11
- Pages
- 2360-2368
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1977606691
- Cited by
- 101
- References
- 47
- Citations by year
- 2026: 2 · 2025: 4 · 2022: 4 · 2021: 5 · 2020: 4 · 2019: 4 · 2018: 4 · 2017: 6 · 2016: 9 · 2015: 6 · 2014: 4 · 2013: 9 · 2012: 3
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH 72832, U01MH072832)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- insulin-like growth factor I, anxiolytic effects, antidepressant effects, IGF-1 receptor, neurotrophic factors, depression, anxiety, intracerebroventricular administration, elevated zero maze, tail suspension test, four-plate test
- MeSH terms
- Analysis of Variance, Animals, Antidepressive Agents, Anxiety, Avoidance Learning, Behavior, Animal, Catechols, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Interactions, Enzyme Inhibitors, Gene Expression Regulation, Injections, Intraventricular, Insulin-Like Growth Factor I, Isoquinolines, Male, Motor Activity, Insulin-Like Growth Factor Binding Proteins, Hindlimb Suspension, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.